Monthly Archives: May 2005

BioMarin Pharmaceutical receives marketing approval for amifampridine phosphate BioMarin Pharmaceutical Inc. announced today that the European Commission has granted marketing approval for 3,4-diaminopyridine (amifampridine phosphate), for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS). Beating Prostate Cancer (Hormonal Therapy … Continue reading →